University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Characterization of severe asthma worldwide : data from the International Severe Asthma Registry (ISAR)

Simple item page
dc.contributor.authorEileen, Wang
dc.contributor.authorWechsler, Michael E
dc.contributor.authorTran, Trung N
dc.contributor.authorHeaney, Liam G
dc.contributor.authorJones, Rupert C
dc.contributor.authorMenzies-Gow, Andrew N
dc.contributor.authorBusby, John
dc.contributor.authorJackson, David J
dc.contributor.authorPfeffer, Paul E
dc.contributor.authorRhee, Chin Kook
dc.contributor.authorCho, You Sook
dc.contributor.authorCanonica, G Walter
dc.contributor.authorHeffler, Enrico
dc.contributor.authorGibson, Peter G
dc.contributor.authorHew, Mark
dc.contributor.authorPeters, Matthew
dc.contributor.authorHarvey, Erin S
dc.contributor.authorAlacqua, Mariana
dc.contributor.authorZangrilli, James
dc.contributor.authorBulathsinhala, Lakmini
dc.contributor.authorCarter, Victoria A
dc.contributor.authorChaudhry, Isha
dc.contributor.authorEleangovan, Neva
dc.contributor.authorHosseini, Naeimeh
dc.contributor.authorMurray, Ruth B
dc.contributor.authorPrice, David B
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.date.accessioned2020-05-07T08:55:01Z
dc.date.available2020-05-07T08:55:01Z
dc.date.issued2020-04-01
dc.descriptionFunding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following: E. W. has received advisory board fees from AstraZeneca. She has been an investigator on clinical trials sponsored by GlaxoSmithKline, Teva, AstraZeneca, Novartis, National Institute of Allergy and Infectious Diseases (NIAID) for which her institution has received funding. She has received funding for investigator-initiated studies from Self Care Catalysts, Genentech, and GlaxoSmithKline. M. E. W. has received consulting honoraria from AstraZeneca plc, Boehringer Ingelheim, Genentech Inc, GlaxoSmithKline plc, Novartis International AG, Regeneron Pharmaceuticals Inc, Sanofi SA, Teva Pharmaceutical Industries Ltd and Equillium. T. N. T., M. A., and J. Z. are employees of AstraZeneca plc, a cofunder of the International Severe Asthma Registry. L. G. H. is Academic Lead for the UK MRC Consortium for Stratified Medicine in Severe Asthma - Industrial Pharma partners Amgen, AstraZeneca, Medimmune, Janssen, Novartis, Roche / Genentech, GlaxoSmithKline, and Boehringer Ingelheim; prior project grant funding from Medimmune, Novartis UK, Roche / Genentech, and GlaxoSmithKline; has taken part in Advisory Boards / Lectures supported by Novartis,Roche / Evelo Biosciences, Genentech, GlaxoSmithKline, Teva, Theravance and Vectura; has travel funding support to international respiratory meetings (AstraZeneca, Chiesi, Novartis, Boehringer Ingelheim, Teva, and GlaxoSmithKline) and has taken part in asthma clinical trials (GlaxoSmithKline, Schering Plough, Synairgen, Novartis, and Roche / Genentech) for which his institution was remunerated. R. C. J. declares grants from AstraZeneca, GlaxoSmithKline, and Novartis; and personal fees for consultancy, speakers fees, or travel support from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Nutricia, Observational & Pragmatic Research Institute, and Pfizer. A. N. M. G. declares grants from AstraZeneca plc, Boehringer Ingelheim, GlaxoSmithKline plc, and Hoffmann La Roche AG; consultancy agreements with AstraZeneca plc, Sanofi SA, and Vectura Group plc; attendance at advisory boards for AstraZeneca plc, Boehringer Ingelheim, GlaxoSmithKline plc, Novartis International AG, Sanofi SA, and Teva Pharmaceutical Industries Ltd; speaker fees from AstraZeneca plc, Boehringer Ingelheim, Novartis International AG, Teva Pharmaceutical Industries Ltd, and Vectura Group plc; and attendance at international conferences for Boehringer Ingelheim and Teva Pharmaceutical Industries Ltd. D. J. J. has received advisory board and speaker fees from AstraZeneca plc, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline plc, Napp Pharmaceuticals Limited, Novartis International AG, and Teva Pharmaceutical Industries Ltd and research grant funding from AstraZeneca plc. P. E. P. has attended advisory boards for Novartis International AG; has given lectures at meetings supported by AstraZeneca plc and GlaxoSmithKline plc; and has taken part in clinical trials sponsored by AstraZeneca plc, GlaxoSmithKline plc, and Novartis International AG, for which his institution received remuneration. C. K. R. declares consultancy and lecture fees from AstraZeneca plc, Boehringer Ingelheim, GlaxoSmithKline plc, Merck Sharp & Dohme Ltd, Mundipharma International Limited, Novartis International AG, Sandoz, Takeda Pharmaceutical Company Limited, and Teva-Handok Pharma Co Ltd. G. W. C. has received research grants and lecture or advisory board fees from A. Menarini Diagnostics Ltd, Allergy Therapeutics PLC, ALK-Abelló A/S, Anallergo SpA, AstraZeneca plc, Boehringer Ingelheim, Chiesi Farmaceutici, Circassia Pharmaceuticals, Danone SA, Faes Farma, Genentech Inc, Genzyme/Regeneron, GlaxoSmithKline plc, HAL Allergy Group, Laboratori Guidotti spa, Malesci Istituto Farmacobiologico spa, MedImmune LLC, Merck & Co Inc, Merck Sharp & Dohme Ltd, Mundipharma International Limited, Novartis International AG, Orion Pharma Ltd, Sanofi SA, Stallergenes Greer Ltd, Teva Pharmaceutical Industries Ltd, Thermo Fisher Scientific, UCB Pharmaceuticals, Uriach Group, and Valeas SpA. E. H. participates in speaking activities and industry advisory committees for AstraZeneca, Sanofi-Genzyme, GSK, Novartis, TEVA, Circassia and Nestlè Purina. P. G. G. declares speaker fees and grants to his institution from AstraZeneca plc, GlaxoSmithKline plc, and Novartis International AG for unrelated projects. M. H. has received grants-in-aid, speaker fees, and fees for serving on the advisory boards of; GlaxoSmithKline, AstraZeneca, Novartis, Teva, and Sanofi, all unrelated to the current manuscript, and all paid to his institutional employer Alfred Health. M. P. declares personal fees and nonfinancial support from AstraZeneca and GlaxoSmithKline. L. B., V. A. C., I. C., N. E., and N. H. are employees of Optimum Patient Care Global Ltd, a cofunder of the International Severe Asthma Registry. D. B. P. has board membership with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals, Thermofisher; consultancy agreements with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Mundipharma, Mylan, Novartis, Thermofisher; funding for patient enrolment or completion of research from Novartis; stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment. None declared (J. B., Y. S. C., E. S. H., R. B. M.).en
dc.description.statusPeer revieweden
dc.format.extent15
dc.format.extent607964
dc.identifier153265896
dc.identifier9745ee2c-6c22-4c12-8612-84682b4b9b15
dc.identifier31785254
dc.identifier85081611905
dc.identifier000523616200026
dc.identifier.citationEileen, W, Wechsler, M E, Tran, T N, Heaney, L G, Jones, R C, Menzies-Gow, A N, Busby, J, Jackson, D J, Pfeffer, P E, Rhee, C K, Cho, Y S, Canonica, G W, Heffler, E, Gibson, P G, Hew, M, Peters, M, Harvey, E S, Alacqua, M, Zangrilli, J, Bulathsinhala, L, Carter, V A, Chaudhry, I, Eleangovan, N, Hosseini, N, Murray, R B & Price, D B 2020, 'Characterization of severe asthma worldwide : data from the International Severe Asthma Registry (ISAR)', Chest, vol. 157, no. 4, pp. 790-804. https://doi.org/10.1016/j.chest.2019.10.053en
dc.identifier.doi10.1016/j.chest.2019.10.053
dc.identifier.iss4en
dc.identifier.issn0012-3692
dc.identifier.otherunpaywall: 10.1016/j.chest.2019.10.053
dc.identifier.urihttps://hdl.handle.net/2164/14253
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85081611905&partnerID=8YFLogxKen
dc.identifier.vol157en
dc.language.isoeng
dc.relation.ispartofChesten
dc.subjectbiologicsen
dc.subjectco-morbidityen
dc.subjecteosinophilsen
dc.subjectFeNOen
dc.subjectIgEen
dc.subjectR Medicineen
dc.subjectCritical Care and Intensive Care Medicineen
dc.subjectCardiology and Cardiovascular Medicineen
dc.subjectPulmonary and Respiratory Medicineen
dc.subjectSupplementary Dataen
dc.subject.lccRen
dc.titleCharacterization of severe asthma worldwide : data from the International Severe Asthma Registry (ISAR)en
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
wang_et_al_characterization_severe_chest_vor.pdf
Size:
593.71 KB
Format:
Adobe Portable Document Format
Download

Collections

All research